β-Adrenoceptors as molecular targets in the treatment of hypertension

Canadian Journal of Cardiology

Volumn 30, Issue 5 S, 2014, Pages S3-

  Ferguson, Stephen S G ^a   Feldman, Ross D ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ARRESTIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; DOPAMINE; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR KINASE; GUANINE NUCLEOTIDE BINDING PROTEIN; LEUKOTRIENE; MITOGEN ACTIVATED PROTEIN KINASE 3; PARTIAL AGONIST; PROSTANOID; THROMBOXANE A2; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOCONSTRICTOR AGENT; VASOPRESSIN;

ADRENERGIC ACTIVITY; ALTERNATIVE RNA SPLICING; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CATECHOLAMINE RELEASE; CHEMICAL STRUCTURE; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; ENZYME ACTIVE SITE; ENZYME PHOSPHORYLATION; HUMAN; HYPERTENSION; INTRACELLULAR SIGNALING; LIGAND BINDING; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; RECEPTOR DOWN REGULATION; RESEARCH; REVIEW; SIGNAL TRANSDUCTION;

AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; CANADA; FEMALE; GTP-BINDING PROTEINS; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; RECEPTORS, ADRENERGIC, BETA; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84899062131     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2014.01.017     Document Type: Review

References (57)

1. Mazumdar D.C., Mukherji K.L. Rauwolfia in hypertension. JIndian Med Assoc 1950, 19:362-367.
2. Grimson K.S. Total Thoracic and Partial to Total Lumbar Sympathectomy and Celiac Ganglionectomy in the Treatment of Hypertension. Ann Surg 1941, 114:753-775.
3. Vongpatanasin W., Kario K., Atlas S.A., Victor R.G. Central sympatholytic drugs. J Clin Hypertens (Greenwich) 2011, 13:658-661.
4. Veelken R., Schmieder R.E. Overview of alpha 1-adrenoceptor antagonism and recent advances in hypertensive therapy. Am J Hypertens 1996, 9:139S-149S.
5. SoRelle R. National Heart, Lung, and Blood Institute halts part of antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Circulation 2000, 101:E9025.
6. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA 2000, 283:1967-1975.
7. Hackam D.G., Quinn R.R., Ravani P., et al. The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol 2013, 29:528-542.
8. Poirier L., Lacourciere Y. The evolving role of β-adrenergic receptor blockers in managing hypertension. Can J Cardiol 2012, 28:334-340.
9. Brodde O.E. The functional importance of beta 1 and beta 2 adrenoceptors in the human heart. Am J Cardiol 1988, 62:24C-29C.
10. Johnson M. Molecular mechanisms of beta(2)-adrenergic receptor function, response, and regulation. JAllergy Clin Immunol 2006, 117:18-24. quiz 25.
11. Rozec B., Noireaud J., Trochu J.N., Gauthier C. Place of beta 3-adrenoceptors among other beta-adrenoceptor subtypes in the regulation of the cardiovascular system. Arch Mal Coeur Vaiss 2003, 96:905-913.
12. Skeberdis V.A. Structure and function of beta3-adrenergic receptors. Medicina (Kaunas) 2004, 40:407-413.
13. Sibley D.R., Lefkowitz R.J. Beta-adrenergic receptor-coupled adenylate cyclase. Biochemical mechanisms of regulation. Mol Neurobiol 1987, 1:121-154.
14. Dixon R.A., Kobilka B.K., Strader D.J., et al. Cloning of the gene and cDNA for mammalian beta-adrenergic receptor and homology with rhodopsin. Nature 1986, 321:75-79.
15. Lander E.S., Linton L.M., Birren B., et al. Initial sequencing and analysis of the human genome. Nature 2001, 409:860-921.
16. Venter J.C., Adams M.D., Myers E.W., et al. The sequence of the human genome. Science 2001, 291:1304-1351.
17. Rasmussen S.G., Choi H.J., Rosenbaum D.M., et al. Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. Nature 2007, 450:383-387.
18. Rosenbaum D.M., Zhang C., Lyons J.A., et al. Structure and function of an irreversible agonist-beta(2) adrenoceptor complex. Nature 2011, 469:236-240.
19. Rasmussen S.G., DeVree B.T., Zou Y., et al. Crystal structure of the beta2 adrenergic receptor-Gs protein complex. Nature 2011, 477:549-555.
20. Chung K.Y., Rasmussen S.G., Liu T., et al. Conformational changes in the G protein Gs induced by the beta2 adrenergic receptor. Nature 2011, 477:611-615.
21. Kamal F.A., Smrcka A.V., Blaxall B.C. Taking the heart failure battle inside the cell: small molecule targeting of G βλ subunits. J Mol Cell Cardiol 2011, 51:462-467.
22. Ferguson S.S., Barak L.S., Zhang J., Caron M.G. G-protein-coupled receptor regulation: role of GRK receptor kinases and arrestins. Can J Physiol Pharmacol 1996, 74:1095-1110.
23. Krupnick J.G., Benovic J.L. The role of receptor kinases and arrestins in G protein-coupled receptor regulation. Annu Rev Pharmacol Toxicol 1998, 38:289-319.
24. Ferguson S.S. Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol Rev 2001, 53:1-24.
25. Luttrell L.M., Lefkowitz R.J. The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals. JCell Sci 2002, 115(pt 3):455-465.
26. Nantel F., Bonin H., Emorine L.J., et al. The human beta 3-adrenergic receptor is resistant to short term agonist-promoted desensitization. Mol Pharmacol 1993, 43:548-555.
27. Luttrell L.M., Gesty-Palmer D. Beyond desensitization: physiological relevance of arrestin-dependent signalling. Pharmacol Rev 2010, 62:305-330.
28. Ferguson S.S., Downey W.E., Colapietro A.M., et al. Role of beta-arrestin in mediating agonist-promoted G protein-coupled receptor internalization. Science 1996, 271:363-366.
29. Goodman O.B., Krupnick J.G., Santini F., et al. Beta-arrestin acts as a clathrin adaptor in endocytosis of the beta2-adrenergic receptor. Nature 1996, 383:447-450.
30. Laporte S.A., Oakley R.H., Zhang J., et al. The beta2-adrenergic receptor/betaarrestin complex recruits the clathrin adaptor AP-2 during endocytosis. Proc Natl Acad Sci U S A 1999, 96:3712-3717.
31. Luttrell L.M., Ferguson S.S., Daaka Y., et al. Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Science 1999, 283:655-661.
32. Luttrell L.M., Roudabush F.L., Choy E.W., et al. Activation and targeting of extracellular signal-regulated kinases by beta-arrestin scaffolds. Proc Natl Acad Sci U S A 2001, 98:2449-2454.
33. Tohgo A., Pierce K.L., Choy E.W., Lefkowitz R.J., Luttrell L.M. beta-Arrestin scaffolding of the ERK cascade enhances cytosolic ERK activity but inhibits ERK-mediated transcription following angiotensin AT1a receptor stimulation. JBiol Chem 2002, 277:9429-9436.
34. McDonald P.H., Chow C.W., Miller W.E., et al. Beta-arrestin 2: a receptor-regulated MAPK scaffold for the activation of JNK3. Science 2000, 290:1574-1577.
35. Beaulieu J.M., Sotnikova T.D., Marion S., et al. An Akt/beta-arrestin 2/PP2A signalling complex mediates dopaminergic neurotransmission and behavior. Cell 2005, 122:261-273.
36. Claing A., Chen W., Miller W.E., et al. beta-Arrestin-mediated ADP-ribosylation factor 6 activation and beta 2-adrenergic receptor endocytosis. JBiol Chem 2001, 276:42509-42513.
37. Barnes W.G., Reiter E., Violin J.D., et al. beta-Arrestin 1 and Galphaq/11 coordinately activate RhoA and stress fiber formation following receptor stimulation. JBiol Chem 2005, 280:8041-8050.
38. Bhattacharya M., Anborgh P.H., Babwah A.V., et al. Beta-arrestins regulate a Ral-GDS Ral effector pathway that mediates cytoskeletal reorganization. Nat Cell Biol 2002, 4:547-555.
39. Mukherjee S., Gurevich V.V., Jones J.C., et al. The ADP ribosylation factor nucleotide exchange factor ARNO promotes beta-arrestin release necessary for luteinizing hormone/choriogonadotropin receptor desensitization. Proc Natl Acad Sci U S A 2000, 97:5901-5906.
40. Luttrell L., Kenakin T. Refining efficacy: Allosterism and bias in G protein-coupled receptor signaling. Methods Mol Biol 2011, 756:3-35.
41. Kenakin T. Functional selectivity through protean and biased agonism: who steers the ship?. Mol Pharmacol 2007, 72:1393-1401.
42. Galandrin S., Oligny-Longpre G., Bouvier M. The evasive nature of drug efficacy: implications for drug discovery. Trends Pharmacol Sci 2007, 28:423-430.
43. Kenakin T., Christopoulos A. Measurements of ligand bias and functional affinity. Nat Rev Drug Discov 2013, 12:483.
44. Wisler J.W., DeWire S.M., Whalen E.J., et al. Aunique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci U S A 2007, 104:16657-16662.
45. Lee M.H., El-Shewy H.M., Luttrell D.K., Luttrell L.M. Role of beta-arrestin-mediated desensitization and signaling in the control of angiotensin AT1a receptor-stimulated transcription. JBiol Chem 2008, 283:2088-2097.
46. Deupi X., Kobilka B.K. Energy landscapes as a tool to integrate GPCR structure, dynamics, and function. Physiology (Bethesda) 2010, 25:293-303.
47. Esler M., Lambert G., Jennings G. Increased regional sympathetic nervous activity in human hypertension: causes and consequences. JHypertens Suppl 1990, 8:S53-S57.
48. Feldman R.D., Gros R. Defective vasodilatory mechanisms in hypertension: a G-protein-coupled receptor perspective. Curr Opin Nephrol Hypertens 2006, 15:135-140.
49. Feldman R.D., Gros R. Impaired vasodilator function in hypertension: the role of alterations in receptor-G protein coupling. Trends Cardiovasc Med 1998, 8:297-305.
50. Suzuki Y., Kuwajima I., Hoshino S., et al. Cardiac performance in elderly hypertensive patients with left ventricular hypertrophy: responses to isometric exercise and beta-agonists. JCardiovasc Pharmacol 1991, 17(suppl 2):S129-S132.
51. Esler M.D. Catecholamines and essential hypertension. Baillieres Clin Endocrinol Metab 1993, 7:415-438.
52. Goldstein D.S. Plasma catecholamines and essential hypertension. An analytical review. Hypertension 1983, 5:86-99.
53. Feldman R.D., Limbird L.E., Nadeau J., Robertson D., Wood A.J. Leukocyte beta-receptor alterations in hypertensive subjects. JClin Invest 1984, 73:648-653.
54. Feldman R.D. Beta-adrenergic receptor alterations in hypertension-physiological and molecular correlates. Can J Physiol Pharmacol 1987, 65:1666-1672.
55. Gros R., Benovic J.L., Tan C.M., Feldman R.D. G-protein-coupled receptor kinase activity is increased in hypertension. JClin Invest 1997, 99:2087-2093.
56. Feldman R.D., Lawton W.J., McArdle W.L. Low sodium diet corrects the defect in lymphocyte beta-adrenergic responsiveness in hypertensive subjects. JClin Invest 1987, 79:290-294.
57. Feldman R.D. Defective venous beta-adrenergic response in borderline hypertensive subjects is corrected by a low sodium diet. JClin Invest 1990, 85:647-652.